VeraDermics (Series B)

Funding Details
Awarder
Inbox
Date Award
December 11, 2024
Vertical
Biopharmaceutical
Funding URL
View Funding Page
Funding Amount:
$75,000,000
Company Info
Traction
The first patient has been dosed in the pivotal Phase 2/3 trial evaluating VDPHL01 in AGA/PHL, which will enroll approximately 480 patients across 44 sites in the United States.
Company Description
VeraDermics is a dermatology company that creates novel drug delivery mechanisms for a pain-free cure for skin conditions such as warts.
Market
Aesthetics and dermatology
Location
New Haven, Connecticut, United States
Coinvestors
Longitude Capital, Surveyor Capital, Osage University Partners, PhiFund, JW Childs Associates, Connecticut Innovations, Vlad Coric, MD
Links
Back to Home Back to Biopharmaceutical Deals View Funding Announcement